Patient Assistance Program (PAP) – Entyvio®

Takeda’s Patient Assistance Programs (PAPs) aim to address local healthcare needs through innovative financing models. PAPs use different collaborative financing models where patients, Takeda, and at times local authorities, foundations, medical associations, charities and other parties, share the cost of treatment. The objective of this program is to allow patients to have access to and complete their entire course of our specialty medicine Adcetris® (brentuximab vedotin), for the treatment of Hodgkin’s Lymphoma, even if they cannot afford to pay for it in full, through an affordability-based approach.
PAPs are implemented in countries in which Takeda is present, that have evolving healthcare systems, where a need for equitable pricing is identified, and where it is allowed by governments and the applicable laws. PAPs for Adcetris® are currently live in 13 countries (Egypt, Hong Kong, Indonesia, Kenya, Lebanon, Malaysia, Mexico, Peru, the Philippines, Singapore, Thailand, UAE and Ukraine).
Knowing that there are significant disparities in healthcare provision both within and between countries, we have adopted a personalised pricing approach rather than providing standard discounts or different tiers of pricing by GDP per capita. Delivered together with Axios International, our implementation partner, the program utilises an advanced means-based assessment tool – the Patient Financial Eligibility Tool (PFET) – that allows Axios International to determine the appropriate, individual payment scheme for each patient. In select cases, for patients with no affordability, and where appropriate and feasible, Takeda may explore other potential routes available for them to access medicines included in the PAPs. What makes the tool particularly innovative is its unique ability to segment the entire market, unlike any other patient assessment tools currently available in the market.
Axios carries out a communications campaign to inform patients and healthcare professionals about the program. Interested parties can then get in touch with Axios to request access to Adcetris® (brentuximab vedotin). Patients are also referred to the PAP by their prescribing physician. The patient and physician complete, sign and submit a single application form. Once submitted, patients undergo a confidential means-based assessment administered by Axios using PFET. Axios ensures that only eligible healthcare professionals are authorized to prescribe Adcetris® (brentuximab vedotin) in adherence to local regulations. The delivery of the specialty care medicine to the prescribing physician is managed by Axios, who further oversee the treatment. Patients enrolled in the program receive ongoing follow-up from Axios to ensure they are adhering to their treatment plan and to their physician’s recommendations.
Takeda is taking a phased approach to the rollout of our PAPs, focusing on eligible patients living in countries with evolving healthcare systems with high unmet medical needs. Our aspiration is to extend the reach of PAPs into all countries that do not have sufficiently developed healthcare systems and where there is limited reimbursement for medical expenses and where appropriate. We also aim to include other specialty medicines in our PAP, and are currently investigating the feasibility of offering a PAP for Ninlaro® for multiple myeloma.
Continuing to improve access to our specialty care products for as many patients as possible requires the integrity of our programs to be sound. We have a robust governance process in place for the consideration, approval and implementation of new programs, and a dedicated governance committee responsible for reviewing and approving the designs of our collaborative financing initiatives in consultation with other functional counterparts.

for more information

Full IFPMA Partner Directory